Literature DB >> 29056421

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.

Ilaria Lamberto1, Xiaoxi Liu1, Hyuk-Soo Seo1, Nathan J Schauer1, Roxana E Iacob2, Wanyi Hu1, Deepika Das3, Tatiana Mikhailova4, Ellen L Weisberg3, John R Engen2, Kenneth C Anderson3, Dharminder Chauhan3, Sirano Dhe-Paganon5, Sara J Buhrlage6.   

Abstract

Deubiquitinating enzymes (DUBs) have garnered significant attention as drug targets in the last 5-10 years. The excitement stems in large part from the powerful ability of DUB inhibitors to promote degradation of oncogenic proteins, especially proteins that are challenging to directly target but which are stabilized by DUB family members. Highly optimized and well-characterized DUB inhibitors have thus become highly sought after tools. Most reported DUB inhibitors, however, are polypharmacological agents possessing weak (micromolar) potency toward their primary target, limiting their utility in target validation and mechanism studies. Due to a lack of high-resolution DUB⋅small-molecule ligand complex structures, no structure-guided optimization efforts have been reported for a mammalian DUB. Here, we report a small-molecule⋅ubiquitin-specific protease (USP) family DUB co-structure and rapid design of potent and selective inhibitors of USP7 guided by the structure. Interestingly, the compounds are non-covalent active-site inhibitors.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DUB; HAUSP; USP7; chemical probe; complex structure; crystal structure; crystallography; deubiquitinating enzyme

Mesh:

Substances:

Year:  2017        PMID: 29056421      PMCID: PMC5749250          DOI: 10.1016/j.chembiol.2017.09.003

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  80 in total

Review 1.  Ubiquitin-mediated proteolysis: biological regulation via destruction.

Authors:  A Ciechanover; A Orian; A L Schwartz
Journal:  Bioessays       Date:  2000-05       Impact factor: 4.345

2.  A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing.

Authors:  Yue Zhao; Guillaume Lang; Saya Ito; Jacques Bonnet; Eric Metzger; Shun Sawatsubashi; Eriko Suzuki; Xavier Le Guezennec; Hendrik G Stunnenberg; Aleksey Krasnov; Sofia G Georgieva; Roland Schüle; Ken-Ichi Takeyama; Shigeaki Kato; László Tora; Didier Devys
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

3.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Authors:  Dharminder Chauhan; Ze Tian; Benjamin Nicholson; K G Suresh Kumar; Bin Zhou; Ruben Carrasco; Jeffrey L McDermott; Craig A Leach; Mariaterresa Fulcinniti; Matthew P Kodrasov; Joseph Weinstock; William D Kingsbury; Teru Hideshima; Parantu K Shah; Stephane Minvielle; Mikael Altun; Benedikt M Kessler; Robert Orlowski; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

4.  Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.

Authors:  Chao Chen; Jiemei Song; Jinzheng Wang; Chang Xu; Caiping Chen; Wei Gu; Hongbin Sun; Xiaoan Wen
Journal:  Bioorg Med Chem Lett       Date:  2017-01-10       Impact factor: 2.823

5.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

Review 6.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

7.  Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes.

Authors:  Mikael Altun; Holger B Kramer; Lianne I Willems; Jeffrey L McDermott; Craig A Leach; Seth J Goldenberg; K G Suresh Kumar; Rebecca Konietzny; Roman Fischer; Edward Kogan; Mukram M Mackeen; Joanna McGouran; Svetlana V Khoronenkova; Jason L Parsons; Grigory L Dianov; Benjamin Nicholson; Benedikt M Kessler
Journal:  Chem Biol       Date:  2011-11-23

Review 8.  Activity-based probes for the ubiquitin conjugation-deconjugation machinery: new chemistries, new tools, and new insights.

Authors:  David S Hewings; John A Flygare; Matthew Bogyo; Ingrid E Wertz
Journal:  FEBS J       Date:  2017-03-10       Impact factor: 5.542

Review 9.  Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.

Authors:  Aaron Ciechanover; Yong Tae Kwon
Journal:  Exp Mol Med       Date:  2015-03-13       Impact factor: 8.718

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  61 in total

Review 1.  USP7: Structure, substrate specificity, and inhibition.

Authors:  Alexandra Pozhidaeva; Irina Bezsonova
Journal:  DNA Repair (Amst)       Date:  2019-02-16

Review 2.  Deubiquitinases: Pro-oncogenic Activity and Therapeutic Targeting in Blood Malignancies.

Authors:  Blanca T Gutierrez-Diaz; Wei Gu; Panagiotis Ntziachristos
Journal:  Trends Immunol       Date:  2020-03-02       Impact factor: 16.687

3.  Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis.

Authors:  Sijia Liu; Román González-Prieto; Mengdi Zhang; Paul P Geurink; Raymond Kooij; Prasanna Vasudevan Iyengar; Maarten van Dinther; Erik Bos; Xiaobing Zhang; Sylvia E Le Dévédec; Bob van de Water; Roman I Koning; Hong-Jian Zhu; Wilma E Mesker; Alfred C O Vertegaal; Huib Ovaa; Long Zhang; John W M Martens; Peter Ten Dijke
Journal:  Clin Cancer Res       Date:  2019-12-19       Impact factor: 12.531

4.  Proteomics of broad deubiquitylase inhibition unmasks redundant enzyme function to reveal substrates and assess enzyme specificity.

Authors:  Valentina Rossio; Joao A Paulo; Joel Chick; Bradley Brasher; Steven P Gygi; Randall W King
Journal:  Cell Chem Biol       Date:  2021-01-07       Impact factor: 8.116

5.  Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.

Authors:  Gerald Gavory; Colin R O'Dowd; Matthew D Helm; Jakub Flasz; Elias Arkoudis; Anthony Dossang; Caroline Hughes; Eamon Cassidy; Keeva McClelland; Ewa Odrzywol; Natalie Page; Oliver Barker; Hugues Miel; Timothy Harrison
Journal:  Nat Chem Biol       Date:  2017-12-04       Impact factor: 15.040

6.  Dissenting degradation: Deubiquitinases in cell cycle and cancer.

Authors:  Thomas Bonacci; Michael J Emanuele
Journal:  Semin Cancer Biol       Date:  2020-03-20       Impact factor: 15.707

Review 7.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

8.  New aspects of USP30 biology in the regulation of pexophagy.

Authors:  Elena Marcassa; Andreas Kallinos; Jane Jardine; Emma V Rusilowicz-Jones; Michael J Clague; Sylvie Urbé
Journal:  Autophagy       Date:  2019-06-09       Impact factor: 16.016

9.  Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis.

Authors:  Yesid A Ramirez; Thomas B Adler; Eva Altmann; Theresa Klemm; Christian Tiesmeyer; Florian Sauer; Stefan G Kathman; Alexander V Statsyuk; Christoph Sotriffer; Caroline Kisker
Journal:  ChemMedChem       Date:  2018-09-06       Impact factor: 3.466

10.  Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors.

Authors:  Colin R O'Dowd; Matthew D Helm; J S Shane Rountree; Jakub T Flasz; Elias Arkoudis; Hugues Miel; Peter R Hewitt; Linda Jordan; Oliver Barker; Caroline Hughes; Ewelina Rozycka; Eamon Cassidy; Keeva McClelland; Ewa Odrzywol; Natalie Page; Stephanie Feutren-Burton; Scarlett Dvorkin; Gerald Gavory; Timothy Harrison
Journal:  ACS Med Chem Lett       Date:  2018-02-21       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.